Skip Navigation



European Heart Journal Advance Access published online on October 7, 2008
European Heart Journal, doi:10.1093/eurheartj/ehn448
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
29/21/2583    most recent
ehn448v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rees, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rees, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Familial hypercholesterolaemia: underdiagnosed and undertreated

Alan Rees*

Department of Medicine, University Hospital of Wales, Heath Park, Cardiff CF14 4XW, UK

* Corresponding author. Tel: +44 29 20743000, Fax: +44 29 20744581, Email: alan.rees@cardiffandvale.wales.nhs.uk

This editorial refers to ‘Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study’{dagger} by A. Neil et al., on page 2625

The first 10% of the full text of this article appears below.

Autosomal dominant familial hypercholesterolaemia (FH) is the most common inherited disorder known to cause premature coronary heart disease in people of European descent. The estimated prevalence of FH is 1 in 500, and heterozygous FH carries a high risk of premature coronary disease if left untreated (>50% risk in men by the age of 50 and >30% in women by 60 years). However, the condition is underdiagnosed and it is estimated that <20% of index cases are ascertained. With the notable exception of The Netherlands, there is generally a complete lack of organization in European countries to ensure the delivery of systematic care such as an established cascade screening programme and a genetic register for FH.

. . . [Full Text of this Article]

Clinical implications


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study
Andrew Neil, Jackie Cooper, John Betteridge, Nigel Capps, Ian McDowell, Paul Durrington, Mary Seed, Steve E. Humphries, and on behalf of the Simon Broome Familial Hyperlipidaemia Register Group
EHJ 2008 29: 2625-2633. [Abstract] [FREE Full Text]